?
?
?
Participants:
Adults who had not been vaccinated against or exposed to SARS-CoV-2, who then received 2 doses of either BNT162b2 or mRNA-1273.
Measurements:
Serum nAB titer at 1 month and 6 months after the second vaccine dose. Daily symptom surveys and objective biometric measurements at each dose.
Results:
363 participants were included in symptom-related analyses (65.6% female; mean age, 52.4 years [SD, 11.9]), and 147 were included in biometric-related analyses (66.0% female; mean age, 58.8 years [SD, 5.3]). Chills, tiredness, feeling unwell, and headache after the second dose were each associated with 1.4 to 1.6 fold higher nAB at 1 and 6 months after vaccination. Symptom count and vaccination-induced change in skin temperature and heart rate were all positively associated with nAB across both follow-up time points. Each 1?°C increase in skin temperature after dose 2 was associated with 1.8 fold higher nAB 1 month later and 3.1 fold higher nAB 6 months later.
?
?
?
?
Potential long-term risks?
?
-
The reverse transcription of mRNA copies can disrupt coding regions and increase the risk of mutations in tumor suppressor genes.
-
The activation of RNA and DNA sensory pathways can lead to the production of pro-inflammatory cytokines, which can cause autoinflammatory and autoimmune conditions.